Aemetis (NASDAQ:AMTX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Aemetis (NASDAQ:AMTX) to a sell rating in a report released on Friday morning.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Aemetis in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.95.

Aemetis Price Performance

Aemetis stock opened at $2.97 on Friday. The business has a 50 day simple moving average of $3.27 and a 200 day simple moving average of $2.97. The company has a market capitalization of $147.71 million, a PE ratio of -1.31 and a beta of 1.47. Aemetis has a one year low of $2.10 and a one year high of $7.03.

Aemetis (NASDAQ:AMTX) last issued its quarterly earnings data on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. The company had revenue of $81.44 million for the quarter, compared to the consensus estimate of $77.79 million. During the same period in the previous year, the business posted ($0.59) earnings per share. Equities analysts anticipate that Aemetis will post -2.02 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aemetis

Institutional investors have recently modified their holdings of the stock. FMR LLC grew its stake in shares of Aemetis by 68.2% during the third quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock valued at $52,000 after purchasing an additional 9,137 shares during the last quarter. Hutchinson Capital Management CA acquired a new position in Aemetis during the 2nd quarter worth $70,000. Barclays PLC boosted its position in Aemetis by 274.6% in the 3rd quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock valued at $109,000 after buying an additional 34,816 shares during the last quarter. Rhumbline Advisers boosted its position in Aemetis by 2,837.1% in the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after buying an additional 50,528 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Aemetis by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 924,293 shares of the specialty chemicals company’s stock valued at $2,126,000 after buying an additional 66,031 shares during the period. 27.02% of the stock is owned by institutional investors.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.